Ann Arbor Esperion Therapeutics’ Stock Rises 35.1 Percent
SHARES OF ESPERION Therapeutics surged in aftermarket trading Wednesday after the company reported positive clinical trial results for its experimental high-cholesterol drug ETC-1002.
The company said patients who were treated with…